Abstract
Genetic Engineering & Biotechnology NewsVol. 40, No. 7 Drug Discovery TutorialEliminating Bottlenecks in mAb Drug DiscoveryTwist Biopharma's approach to antibody discovery incorporates phage display to generate massive antibody libraries, and high-throughput surface plasmon resonance technology to accelerate screeningAaron Sato, PhDAaron Sato, PhDAaron Sato, PhD, is CSO at Twist Biopharma, a division of Twist Bioscience, based in South San Francisco, CA. Twist Bioscience utilizes its silicon-based DNA synthesis platform to generate DNA and DNA-based products for the development of diagnostics, therapeutics, bio-based chemicals, food, DNA-based data storage, and leverages this platform through Twist Biopharma specifically for antibody drug discovery. Website: www.twistbiopharma.com.Search for more papers by this authorPublished Online:10 Jul 2020https://doi.org/10.1089/gen.40.07.13AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 40Issue 7Jul 2020 Information© 2020 by GEN PublishingTo cite this article:Aaron Sato, PhD.Eliminating Bottlenecks in mAb Drug Discovery.Genetic Engineering & Biotechnology News.Jul 2020.48-49.http://doi.org/10.1089/gen.40.07.13Published in Volume: 40 Issue 7: July 10, 2020PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
